288 related articles for article (PubMed ID: 26427454)
41. [Gene Replacement Therapy for Inherited Retinal Dystrophies].
Mühlfriedel R; Sothilingam V; Tanimoto N; Seeliger MW
Klin Monbl Augenheilkd; 2017 Mar; 234(3):320-328. PubMed ID: 28355661
[TBL] [Abstract][Full Text] [Related]
42. Applying next generation sequencing with microdroplet PCR to determine the disease-causing mutations in retinal dystrophies.
Wang X; Zein WM; D'Souza L; Roberson C; Wetherby K; He H; Villarta A; Turriff A; Johnson KR; Fann YC
BMC Ophthalmol; 2017 Aug; 17(1):157. PubMed ID: 28838317
[TBL] [Abstract][Full Text] [Related]
43. Splicing in the immune system: potential targets for therapeutic intervention by antisense-mediated alternative splicing.
Mourich DV; Iversen PL
Curr Opin Mol Ther; 2009 Apr; 11(2):124-32. PubMed ID: 19330718
[TBL] [Abstract][Full Text] [Related]
44. Progress toward therapy with antisense-mediated splicing modulation.
Du L; Gatti RA
Curr Opin Mol Ther; 2009 Apr; 11(2):116-23. PubMed ID: 19330717
[TBL] [Abstract][Full Text] [Related]
45. Nuclear antisense effects in cyclophilin A pre-mRNA splicing by oligonucleotides: a comparison of tricyclo-DNA with LNA.
Ittig D; Liu S; Renneberg D; Schümperli D; Leumann CJ
Nucleic Acids Res; 2004; 32(1):346-53. PubMed ID: 14726483
[TBL] [Abstract][Full Text] [Related]
46. Guidelines for antisense oligonucleotide design and insight into splice-modulating mechanisms.
Aartsma-Rus A; van Vliet L; Hirschi M; Janson AA; Heemskerk H; de Winter CL; de Kimpe S; van Deutekom JC; 't Hoen PA; van Ommen GJ
Mol Ther; 2009 Mar; 17(3):548-53. PubMed ID: 18813282
[TBL] [Abstract][Full Text] [Related]
47. New Editing Tools for Gene Therapy in Inherited Retinal Dystrophies.
Pulman J; Sahel JA; Dalkara D
CRISPR J; 2022 Jun; 5(3):377-388. PubMed ID: 35506982
[TBL] [Abstract][Full Text] [Related]
48. Development of antisense-mediated exon skipping as a treatment for duchenne muscular dystrophy.
Heemskerk H; de Winter CL; van Ommen GJ; van Deutekom JC; Aartsma-Rus A
Ann N Y Acad Sci; 2009 Sep; 1175():71-9. PubMed ID: 19796079
[TBL] [Abstract][Full Text] [Related]
49. Antisense Oligonucleotide Therapy for Ophthalmic Conditions.
Ferenchak K; Deitch I; Huckfeldt R
Semin Ophthalmol; 2021 Aug; 36(5-6):452-457. PubMed ID: 34010086
[TBL] [Abstract][Full Text] [Related]
50. Correction of prototypic ATM splicing mutations and aberrant ATM function with antisense morpholino oligonucleotides.
Du L; Pollard JM; Gatti RA
Proc Natl Acad Sci U S A; 2007 Apr; 104(14):6007-12. PubMed ID: 17389389
[TBL] [Abstract][Full Text] [Related]
51. Modification of pre-mRNA splicing by antisense oligonucleotides.
Kole R
Acta Biochim Pol; 1997; 44(2):231-7. PubMed ID: 9360712
[TBL] [Abstract][Full Text] [Related]
52. Design, development and deployment of a web-based interoperable registry for inherited retinal dystrophies in Portugal: the IRD-PT.
Marques JP; Carvalho AL; Henriques J; Murta JN; Saraiva J; Silva R
Orphanet J Rare Dis; 2020 Oct; 15(1):304. PubMed ID: 33109251
[TBL] [Abstract][Full Text] [Related]
53. Retinal dystrophies and gene therapy.
Sundaram V; Moore AT; Ali RR; Bainbridge JW
Eur J Pediatr; 2012 May; 171(5):757-65. PubMed ID: 22080959
[TBL] [Abstract][Full Text] [Related]
54. Genetic therapies for RNA mis-splicing diseases.
Hammond SM; Wood MJ
Trends Genet; 2011 May; 27(5):196-205. PubMed ID: 21497936
[TBL] [Abstract][Full Text] [Related]
55. Surgical Aspects in Gene Therapy for Inherited Retinal Diseases.
Fischer MD; Bartz-Schmidt KU; Dimopoulos S; Herrmann P; Gerhardt M; Holz FG; Priglinger S
Klin Monbl Augenheilkd; 2021 Mar; 238(3):267-271. PubMed ID: 33618387
[TBL] [Abstract][Full Text] [Related]
56. [Genetic diagnostic testing in inherited retinal dystrophies].
Kohl S; Biskup S
Klin Monbl Augenheilkd; 2013 Mar; 230(3):243-6. PubMed ID: 23208805
[TBL] [Abstract][Full Text] [Related]
57. Functional assays of non-canonical splice-site variants in inherited retinal dystrophies genes.
Rodriguez-Muñoz A; Liquori A; García-Bohorquez B; Jaijo T; Aller E; Millán JM; García-García G
Sci Rep; 2022 Jan; 12(1):68. PubMed ID: 34996991
[TBL] [Abstract][Full Text] [Related]
58. Antisense oligonucleotide therapeutics in clinical trials for the treatment of inherited retinal diseases.
Xue K; MacLaren RE
Expert Opin Investig Drugs; 2020 Oct; 29(10):1163-1170. PubMed ID: 32741234
[TBL] [Abstract][Full Text] [Related]
59. Correction of aberrant pre-mRNA splicing by antisense oligonucleotides in beta-thalassemia Egyptian patients with IVSI-110 mutation.
El-Beshlawy A; Mostafa A; Youssry I; Gabr H; Mansour IM; El-Tablawy M; Aziz M; Hussein IR
J Pediatr Hematol Oncol; 2008 Apr; 30(4):281-4. PubMed ID: 18391696
[TBL] [Abstract][Full Text] [Related]
60. [Genetic ocular diseases].
Hamel CP
Rev Prat; 2015 Apr; 65(4):467-70. PubMed ID: 26058181
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
